CoChat

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study

Open access
Xiao, Yanni, Lu, Di, Lei, Mingxing, Xie, Wenzhuan, Chen, Yaoxu, Zheng, Yating, Wang, Chunli, Zhao, Jing, Zhu, Zhen, Zhao, Xiaochen, Huang, Mengli, Lin, Youen, Li, Zhongjun, Yang, Li · 2021 · Annals of Translational Medicine

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Background: Disruption of the DNA damage repair (DDR) gene is related to cancer progression, treatment selection, and is subjected to radiation and targeted therapies with limited success. This paper conducted a comprehensive analysis to explore the distribution of DDR mutations in Chinese pan-cancer patients. Methods: A total of 10,284 consecutive cases were analyzed in 24 cancer types [non-small cell lung cancer (NSCLC) 29.0%, liver 12.0%, colorectum 10.7%, etc.]. Tumor tissue samples were subjected to next generation sequencing (NGS) using a 381 gene panel incorporating 100 microsatellite loci. The association of deleterious somatic DDR mutation (del-sDDRmut) with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1) expression of pan-cancers was evaluated. Genomic and clinical data from public cohorts of immunotherapy were analyzed to demonstrate the association between del-sDDRmut and clinical survival. Results: Del-sDDRmut were found in 802 (7.6%) of all cases, and were most common in cancers of the endometrium, prostate, bladder, etc. cancer with a higher TMB also had a higher prevalence of mutations in DDR pathways. The results of the ridge regression analysis showed that 20 DDR genes were significantly associated with TMB [false discovery rate (FDR) <0.01]. A total of 8,899 patients had both TMB and MSI-data in pan-cancers. Seventy-four percent of patients with MSI-high (MSI-H) were accompanied by del-sDDRmut/TMB-high (TMB-H). The largest proportion of patients with microsatellite stability (MSS) with DDR mutations were classified as TMB-H. The top 6 tumors (NSCLC, melanoma, esophagus, head and neck, thyroid, and mediastinal) had the highest prevalence of PD-L1 ≥1%, and DDR mutations were significantly associated with a higher percent of PD-L1 positive (P<0.05). Furthermore, in the immune cohort analysis of NSCLC, patients with del-sDDRmut significantly improved median progression-free survival (mPFS) and median overall survival (mOS) compared to wild-type DDR patients (P=0.002 and P=0.043), with higher TMB observed (P<0.001). Conclusions: This study explored the association of DDR mutations with TMB, MSI-H, and PD-L1 expression, and revealed that patients with DDR mutations have a significantly improve prognosis than wild-type patients on immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm-21-5449

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mutual exclusion of sDDRmut and gDDRmut. sDDRmut, somatic DDR mutation; gDDRmut, germline DDR mutations; DDR, DNA damage repair; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining; TMB, tumor mutational burden; TMB-H, TMB-high; TMB-L, TMB-low.
Figure 1 Mutual exclusion of sDDRmut and gDDRmut. sDDRmut, somatic DDR mutation; gDDRmut, germline DDR mutations; DDR, DNA damage repair; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining; TMB, tumor mutational burden; TMB-H, TMB-high; TMB-L, TMB-low.CC BY-NC-ND · PubMed Central
Figure 2 Analysis of somatic DDR gene alterations in pan cancer. (A) Somatic DDR gene mutations are frequently and unevenly distributed types and frequencies of cancer types. (B) Somatic DDR pathway mutations are frequently and unevenly distributed types and frequencies of cancer types. (C) Mutual exclusion of somatic mutations in different DDR pathways. DDR, DNA damage repair; SCLC, small cell lung cancer; GIST, gastrointestinal stromal tumor; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining.
Figure 2 Analysis of somatic DDR gene alterations in pan cancer. (A) Somatic DDR gene mutations are frequently and unevenly distributed types and frequencies of cancer types. (B) Somatic DDR pathway mutations are frequently and unevenly distributed types and frequencies of cancer types. (C) Mutual exclusion of somatic mutations in different DDR pathways. DDR, DNA damage repair; SCLC, small cell lung cancer; GIST, gastrointestinal stromal tumor; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining.CC BY-NC-ND · PubMed Central
Figure 3 The association of DDR alterations with MSI status and TMB. (A) Magnitude and meaningful volcano plot of the DDR gene ridge. (B) The Venn diagram shows overlapping cases defined by the indicated molecular characteristics. (C) Characteristics of TMB and MSI in cases with GA. (D) MSS samples only: TMB-H prevalence and TMB score box plot for the subgroup with GA in each gene or feature. (E) MSI-H samples only: TMB-H prevalence and TMB score box plot for the subgroup with GA in each gene or feature. * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001, **** indicates P<0.0001. DDR, DNA damage repair; TMB, tumor mutational burden; MSI, microsatellite instability; MSS, microsatellite stability; GA, genetic algorithm; MSI-H, MSI-high; TMB-H, TMB-high; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining.
Figure 3 The association of DDR alterations with MSI status and TMB. (A) Magnitude and meaningful volcano plot of the DDR gene ridge. (B) The Venn diagram shows overlapping cases defined by the indicated molecular characteristics. (C) Characteristics of TMB and MSI in cases with GA. (D) MSS samples only: TMB-H prevalence and TMB score box plot for the subgroup with GA in each gene or feature. (E) MSI-H samples only: TMB-H prevalence and TMB score box plot for the subgroup with GA in each gene or feature. * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001, **** indicates P<0.0001. DDR, DNA damage repair; TMB, tumor mutational burden; MSI, microsatellite instability; MSS, microsatellite stability; GA, genetic algorithm; MSI-H, MSI-high; TMB-H, TMB-high; BER, base excision repair; NER, nucleotide excision repair; MMR, mismatch repair; DS, damage sensor; FA, Fanconi anemia; HR, homology-dependent recombination; NHEJ, non-homologous end joining.CC BY-NC-ND · PubMed Central
Figure 4 The association of DDR alterations and PD-L1 expression. (A) The prevalence of positive PD-L1 TPS across 24 tumors. (B) The association of positive PD-L1 TPS with DDR genes or pathways alteration. DDR, DNA damage repair; PD-L1, programmed cell death-ligand 1; TPS, tumor proportion score.
Figure 4 The association of DDR alterations and PD-L1 expression. (A) The prevalence of positive PD-L1 TPS across 24 tumors. (B) The association of positive PD-L1 TPS with DDR genes or pathways alteration. DDR, DNA damage repair; PD-L1, programmed cell death-ligand 1; TPS, tumor proportion score.CC BY-NC-ND · PubMed Central
Figure 5 The association of del-sDDRmut and immunotherapy in NSCLC. (A) Meta-analysis of survival for del-sDDRmut in NSCLC among five independent immunotherapy cohorts. (B-a) Correlation between del-sDDRmut and PFS in immunotherapy cohorts. (B-b) Correlation between del-sDDRmut and OS in immunotherapy cohorts. (C-a) Correlation between del-sDDRmut and TMB in different groups. (C-b) The ORR of immunotherapy in different groups. del-sDDRmut, deleterious somatic DDR mutation; DDR, DNA damage repair; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; mPFS, median PFS; mOS, median OS; TMB, tumor mutational burden; ORR, objective response rate.
Figure 5 The association of del-sDDRmut and immunotherapy in NSCLC. (A) Meta-analysis of survival for del-sDDRmut in NSCLC among five independent immunotherapy cohorts. (B-a) Correlation between del-sDDRmut and PFS in immunotherapy cohorts. (B-b) Correlation between del-sDDRmut and OS in immunotherapy cohorts. (C-a) Correlation between del-sDDRmut and TMB in different groups. (C-b) The ORR of immunotherapy in different groups. del-sDDRmut, deleterious somatic DDR mutation; DDR, DNA damage repair; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; mPFS, median PFS; mOS, median OS; TMB, tumor mutational burden; ORR, objective response rate.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 22

Metadata

Authors
Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., Huang, M., Lin, Y., Li, Z., & Yang, L.
Affiliations
  • Army Medical University (CN)
  • Nanfang Hospital (CN)
  • Chongqing University (CN)
  • 3D Medicines, Inc. (China) (CN)
  • Traditional Chinese Medicine Hospital of Kunshan (CN)
  • Jieyang People's Hospital (CN)
Corresponding author
  • Lin, Youen
  • Li, Zhongjun
Venue
Annals of Translational Medicine
Published
2021-11
Volume
9
Issue
22
Pages
1661-1661
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
OpenAlex
W3217378264
Cited by
22
References
45
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4
FWCI
1.59
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
DNA repair, somatic mutations, tumor mutational burden, microsatellite instability, PD-L1 expression, pan-cancer, non-small cell lung cancer, immunotherapy response, progression-free survival, overall survival, Chinese patients, endometrial cancer, prostate cancer, bladder cancer, melanoma, esophageal cancer, head and neck cancer, thyroid cancer, mediastinal cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study. https://app.cochat.ai/papers/10.21037/atm-21-5449
The paper
Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., Huang, M., Lin, Y., Li, Z., & Yang, L. (2021). Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study. Annals of Translational Medicine. https://doi.org/10.21037/atm-21-5449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.